Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 19.69 0.75 (3.96%) Market Cap: 1.68 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 3.85 GF Score: 41/100

Q2 2019 Syndax Pharmaceuticals Inc Earnings Call Transcript

Aug 07, 2019 / 08:30PM GMT
Release Date Price: $9.51 (+4.05%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Syndax Second Quarter 2019 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Ms. Melissa Forst of Argot Partners. Ma'am, please go ahead.

Melissa Forst
Argot Partners, LLC - SVP

Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax's second quarter 2019 financial and operating results. I am Melissa Forst with Argot Partners. And with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call today for the question-and-answer session is Michael Metzger, President and COO; and Dr. Michael Meyers, Chief Medical Officer.

This call is being accompanied by a slide deck that has been posted on the company's website. So I would ask you to please turn to the company's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot